# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria

> **NCT07005713** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 34 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** BGB-16673
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07005713
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-19
- **Primary completion:** 2026-04-17
- **Final completion:** 2026-04-17
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07005713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07005713, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07005713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*